United Therapeutics Corporation $UTHR Shares Acquired by Blue Trust Inc.

Blue Trust Inc. increased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 7.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,235 shares of the biotechnology company’s stock after acquiring an additional 86 shares during the period. Blue Trust Inc.’s holdings in United Therapeutics were worth $355,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. HB Wealth Management LLC increased its stake in shares of United Therapeutics by 2.9% in the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 35 shares during the period. Hohimer Wealth Management LLC increased its position in United Therapeutics by 0.3% in the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company’s stock valued at $3,900,000 after acquiring an additional 37 shares during the period. Park Avenue Securities LLC increased its position in United Therapeutics by 1.7% in the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock valued at $676,000 after acquiring an additional 39 shares during the period. Applied Finance Capital Management LLC increased its holdings in shares of United Therapeutics by 3.7% during the first quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company’s stock valued at $349,000 after purchasing an additional 40 shares during the period. Finally, Headlands Technologies LLC increased its holdings in shares of United Therapeutics by 1.5% during the first quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company’s stock valued at $828,000 after purchasing an additional 40 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $11,356,133.75. The trade was a 23.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The disclosure for this sale can be found here. Insiders sold a total of 261,935 shares of company stock worth $105,561,472 over the last 90 days. Insiders own 10.30% of the company’s stock.

United Therapeutics Price Performance

Shares of UTHR opened at $440.06 on Tuesday. The stock has a market capitalization of $19.85 billion, a P/E ratio of 17.18, a P/E/G ratio of 4.82 and a beta of 0.66. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $459.48. The firm’s 50 day moving average is $375.22 and its 200-day moving average is $324.71.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company’s quarterly revenue was up 11.7% compared to the same quarter last year. During the same quarter last year, the firm posted $5.85 EPS. As a group, equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Bank of America raised their price target on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. UBS Group raised their price objective on shares of United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Royal Bank Of Canada initiated coverage on shares of United Therapeutics in a research note on Friday, September 26th. They set an “outperform” rating and a $569.00 price objective on the stock. Finally, Morgan Stanley raised their price objective on shares of United Therapeutics from $328.00 to $435.00 and gave the company an “equal weight” rating in a research note on Friday. Ten investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $457.21.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.